All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F21%3A10428578" target="_blank" >RIV/00216208:11150/21:10428578 - isvavai.cz</a>

  • Alternative codes found

    RIV/00179906:_____/21:10428578

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=-LxTAm-iyd" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=-LxTAm-iyd</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.3390/cancers13071571" target="_blank" >10.3390/cancers13071571</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

  • Original language description

    Simple Summary Monoclonal antibodies represent a major therapeutic progress in multiple myeloma during the last decade. The use of antibodies as well as antibody drug conjugates has changed the treatment landscape rapidly. The intent of this paper is to summarize the current major results of monoclonal antibody treatments in multiple myeloma. Multiple myeloma is the second most common hematologic malignancy. Current treatment strategies are mainly based on immunomodulatory drugs, proteasome inhibitors or combination of both. Novel agents added to these backbone treatments represent a promising strategy in treatment of newly diagnosed as well as relapsed and refractory multiple myeloma patients. In this respect, the incorporation of monoclonal antibodies into standard-of-care regimens markedly improved prognosis of myeloma patients during the last years. More specifically, monoclonal anti-CD38 antibodies, daratumumab and isatuximab, have been implemented into treatment strategies from first-line treatment to refractory disease. In addition, the monoclonal anti-SLAM-F7 antibody elotuzumab in combination with immunomodulatory drugs has improved the clinical outcomes of patients with relapsed/refractory disease. Belantamab mafodotin is the first approved antibody drug conjugate directed against B cell maturation antigen and is currently used as a monotherapy for patients with advanced disease. This review focuses on clinical efficacy and safety of monoclonal antibodies as well as antibody drug conjugates in multiple myeloma.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Cancers

  • ISSN

    2072-6694

  • e-ISSN

  • Volume of the periodical

    13

  • Issue of the periodical within the volume

    7

  • Country of publishing house

    CH - SWITZERLAND

  • Number of pages

    24

  • Pages from-to

    1571

  • UT code for WoS article

    000638353400001

  • EID of the result in the Scopus database

    2-s2.0-85103122860